ライフサイエンスコーパス: combination vaccine

1 e response to that elicited by the IpaB/IpaD combination vaccine.

2 o be the highest dose level of 3.0 mg of the combination vaccine.

3 ween monovalent RSV cpts-248/404 vaccine and combination vaccine.

4 sponsiveness of the env DNA component in the combination vaccine.

5 strains in humans could be rectified by this combination vaccine.

6 rs [-13.7 to -11.0]) compared with the other combination vaccines.

7 on vaccine constructs were used to develop a combination vaccine against EBOV, SUDV, and BDBV.

8 d with a TLR3 agonist is feasible, also as a combination vaccine against influenza.

9 Vaccination with the combination vaccine also led to enhanced E6-specific CD8

10 Combination vaccines and simultaneous administration of

11 s received a separate consistency lot of the combination vaccine, and 1 group received separate but c

12 ate for the development of new multipathogen combination vaccines, and suggest ways to accelerate the

13 Despite reduced immunogenicity, DTaP-Hib combination vaccines appear to prime for immunologic mem

14 should stimulate interest in assessing this combination vaccine approach in humans.

15 ine manufacturing infrastructure to generate combination vaccines capable of protecting from both inf

16 Immunization with a combination vaccine composed of highly purified native F

17 Furthermore, the combination vaccine conferred significant protection aga

18 ating the potential for the development of a combination vaccine consisting of Invaplex and other imm

19 A combination vaccine consisting of TT adsorbed to alum an

20 Here we report the efficacy of a combination vaccine containing gC2/gD2 and UL19/UL47 for

21 In guinea pigs immunized with a combination vaccine containing HIV env and HIV gag DNA p

22 e used for the assessment of new IPVs and of combination vaccines containing an IPV component.

23 ages 2, 3, and 4 months until 2004, when new combination vaccines containing inactivated poliovirus w

24 component of acellular pertussis-containing combination vaccines (DTaP-Hib) is unclear.

25 ) to either a first dose of a pentavalent wP combination vaccine (DTwP-Hib-HepB, Pentabio PT Bio Farm

26 of guinea pigs or ferrets with the trivalent combination vaccine elicited humoral responses to each o

27 Similarly, the EEEV replicon and V/W/E combination vaccine elicited neutralizing antibodies aga

28 Vaccination with this combination vaccine elicited neutralizing antibodies and

29 The combination vaccine elicited protection that was compara

30 -RBD vaccine has the potential to serve as a combination vaccine for inducing sterilizing immunity ag

31 acterization of a recombinant hypoallergenic combination vaccine for specific immunotherapy of HDM al

32 and Dec 31, 2012, either as individual or as combination vaccines, for all age and sex groups.

33 ce to suggest that physicians should not use combination vaccines in ELBW infants.

34 We previously showed that a combination vaccine incorporating J8-DT (conserved pepti

35 ved as the number of doses of the DTaP/PRP-T combination vaccine increased (P<.02 and P=.01, respecti

36 ears of life has increased, and although new combination vaccines may eventually simplify the schedul

37 a collected from rabbits vaccinated with the combination vaccine neutralized all four targets.

38 The protection induced by a combination vaccine of AMA1 and MSP1 was not superior to

39 gella is endemic, protection studies using a combination vaccine of Shigella sonnei vaccine strain WR

40 ios (including six single vaccines and three combination vaccines) on antibiotic- treated diarrhoea,

41 The hepatitis A portion of the combination vaccine produced clinically acceptable high

42 Rhesus macaques were immunized with a combination vaccine regimen consisting of adenovirus typ

43 PIV3 vaccine; 16 (76%) of 21 children given combination vaccine shed PIV3-cp45 versus 11 (92%) of 12

44 se results demonstrate the potential of this combination vaccine strategy and suggest that vaccine pr

45 using the chimpanzee model to investigate a combination vaccine strategy involving sequential primin

46 The DTaP-PRP-T-HB combination vaccine studied elicits high avidity antibod

47 Incorporating combination vaccines, such as the measles-mumps-rubella-

48 To create a seasonal combination vaccine targeting both influenza viruses and

49 nes cell envelope proteinase, we developed a combination vaccine that is highly effective in blocking

50 he UK has coincided with the distribution of combination vaccines that contain acellular pertussis (D

51 ty of developing new generations of RV-based combination vaccines that provide protection against a s

52 B vaccine (Engerix-B), and hepatitis A and B combination vaccine (Twinrix) were studied using the VAE

53 Treatment with the combination vaccine was also shown to enhance the antitu

54 The combination vaccine was generally well tolerated.

55 e level of protection afforded by WRSd1 in a combination vaccine was lower than the protection elicit

56 tis-Haemophilus influenza type b-hepatitis B combination vaccine were given at 2, 3, and 4 months aft

57 Mice receiving the combination vaccine were strongly protected against pyod

58 CONCLUSION The combination vaccines were safe and effective in elicitin

59 similar across immunization types, including combination vaccines when compared with single-dose vacc

60 d protection with the LION-SUDV and the LION-Combination vaccines, while the LION-EBOV vaccine achiev

61 Combination vaccines will probably be necessary to achie

62 or receptor (HER2) extracellular domain in a combination vaccine with a promiscuous T-cell epitope (i

63 A combination vaccine with M-cell targeted recombinant HA1